Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women

Wern Cherng Cheng, Shyi Chyi Lo, Keh Sung Tsai, Shih Te Tu, Jin-Shang Wu, Ching I. Chang, Chi Ling Chen, Ning Sing Shaw, Hui Yu Peng, Shu Yi Wang, Chih-Hsing Wu, I. Shaw Jan, Ssu Chun Hsu, Chao Wei Liu, Li Na Lee, Tong Yuan Tai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Purpose: Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods: The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results: In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion: The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors.

Original languageEnglish
Pages (from-to)710-716
Number of pages7
JournalJournal of the Formosan Medical Association
Volume114
Issue number8
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

Phytoestrogens
Isoflavones
Liver Function Tests
Placebos
Blood Pressure
Factor VII
Blood Coagulation Factors
Plasminogen Activator Inhibitor 1
Hormone Replacement Therapy
von Willebrand Factor
Therapeutics
Monocytes
Estrogens
Triglycerides
Blood Platelets
Body Weight
Lipids
Safety

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Cheng, Wern Cherng ; Lo, Shyi Chyi ; Tsai, Keh Sung ; Tu, Shih Te ; Wu, Jin-Shang ; Chang, Ching I. ; Chen, Chi Ling ; Shaw, Ning Sing ; Peng, Hui Yu ; Wang, Shu Yi ; Wu, Chih-Hsing ; Jan, I. Shaw ; Hsu, Ssu Chun ; Liu, Chao Wei ; Lee, Li Na ; Tai, Tong Yuan. / Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women. In: Journal of the Formosan Medical Association. 2015 ; Vol. 114, No. 8. pp. 710-716.
@article{c2e98b4c15d846558d83687e75eb5db6,
title = "Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women",
abstract = "Background/Purpose: Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods: The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results: In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion: The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors.",
author = "Cheng, {Wern Cherng} and Lo, {Shyi Chyi} and Tsai, {Keh Sung} and Tu, {Shih Te} and Jin-Shang Wu and Chang, {Ching I.} and Chen, {Chi Ling} and Shaw, {Ning Sing} and Peng, {Hui Yu} and Wang, {Shu Yi} and Chih-Hsing Wu and Jan, {I. Shaw} and Hsu, {Ssu Chun} and Liu, {Chao Wei} and Lee, {Li Na} and Tai, {Tong Yuan}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.jfma.2013.11.001",
language = "English",
volume = "114",
pages = "710--716",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "8",

}

Cheng, WC, Lo, SC, Tsai, KS, Tu, ST, Wu, J-S, Chang, CI, Chen, CL, Shaw, NS, Peng, HY, Wang, SY, Wu, C-H, Jan, IS, Hsu, SC, Liu, CW, Lee, LN & Tai, TY 2015, 'Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women', Journal of the Formosan Medical Association, vol. 114, no. 8, pp. 710-716. https://doi.org/10.1016/j.jfma.2013.11.001

Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women. / Cheng, Wern Cherng; Lo, Shyi Chyi; Tsai, Keh Sung; Tu, Shih Te; Wu, Jin-Shang; Chang, Ching I.; Chen, Chi Ling; Shaw, Ning Sing; Peng, Hui Yu; Wang, Shu Yi; Wu, Chih-Hsing; Jan, I. Shaw; Hsu, Ssu Chun; Liu, Chao Wei; Lee, Li Na; Tai, Tong Yuan.

In: Journal of the Formosan Medical Association, Vol. 114, No. 8, 01.08.2015, p. 710-716.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women

AU - Cheng, Wern Cherng

AU - Lo, Shyi Chyi

AU - Tsai, Keh Sung

AU - Tu, Shih Te

AU - Wu, Jin-Shang

AU - Chang, Ching I.

AU - Chen, Chi Ling

AU - Shaw, Ning Sing

AU - Peng, Hui Yu

AU - Wang, Shu Yi

AU - Wu, Chih-Hsing

AU - Jan, I. Shaw

AU - Hsu, Ssu Chun

AU - Liu, Chao Wei

AU - Lee, Li Na

AU - Tai, Tong Yuan

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background/Purpose: Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods: The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results: In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion: The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors.

AB - Background/Purpose: Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods: The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results: In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion: The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors.

UR - http://www.scopus.com/inward/record.url?scp=84940439438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940439438&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2013.11.001

DO - 10.1016/j.jfma.2013.11.001

M3 - Article

C2 - 24360978

AN - SCOPUS:84940439438

VL - 114

SP - 710

EP - 716

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 8

ER -